Difficulty: Medium
Average Score: 70%
Testbank
An HIV-infected patient presents at the clinic for a scheduled CD4+ count. The results of the test are 45 cells/mL, and the nurse recognizes the patients increased risk for Mycobacterium avium complex (MAC disease). The nurse should anticipate the administration of what drug?
Correct answer
A
Rationale
Azithromycin is the appropriate drug to anticipate for the patient with a CD4+ count of 45 cells/mL due to the increased risk of Mycobacterium avium complex (MAC) disease.
Azithromycin is recommended for prophylaxis against MAC in HIV-infected patients when their CD4+ count falls below 50 cells/mL, as it effectively reduces the risk of opportunistic infections associated with severe immunosuppression.
B: Vancomycin is primarily used to treat infections caused by Gram-positive bacteria, particularly methicillin-resistant Staphylococcus aureus (MRSA), and is not indicated for MAC prophylaxis.
C: Levofloxacin is a fluoroquinolone antibiotic that treats various bacterial infections but does not have a role in preventing Mycobacterium avium complex in immunocompromised patients.
D: Fluconazole is an antifungal medication used to treat fungal infections, particularly cryptococcal meningitis in HIV patients, but it does not provide protection against MAC disease.
Azithromycin is recommended for prophylaxis against MAC in HIV-infected patients when their CD4+ count falls below 50 cells/mL, as it effectively reduces the risk of opportunistic infections associated with severe immunosuppression.
B: Vancomycin is primarily used to treat infections caused by Gram-positive bacteria, particularly methicillin-resistant Staphylococcus aureus (MRSA), and is not indicated for MAC prophylaxis.
C: Levofloxacin is a fluoroquinolone antibiotic that treats various bacterial infections but does not have a role in preventing Mycobacterium avium complex in immunocompromised patients.
D: Fluconazole is an antifungal medication used to treat fungal infections, particularly cryptococcal meningitis in HIV patients, but it does not provide protection against MAC disease.